Shanghai Hengrui Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-12-04
- Employees
- -
- Market Cap
- -
- Website
- http://www.shhrp.com
A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors
Phase 1
- Conditions
- Advanced Malignant Cancer
- Interventions
- Drug: SHR-1909 injection
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05162469
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
Phase 1
Completed
- Conditions
- Advanced Malignant Tumor
- Interventions
- Drug: HRS2398 Tablets
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05144061
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 170
- Registration Number
- NCT05113069
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children
Phase 3
Completed
- Conditions
- Preoperative Sedation of Children
- Interventions
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 159
- Registration Number
- NCT05111431
- Locations
- 🇨🇳
Beijing Children's Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
A Study of HRS2543 in Patients With Advanced Tumors
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05068856
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, Shanghai, China
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
Phase 1
Recruiting
- Conditions
- ER-Positive, HER2-Negative Breast Cancer
- Interventions
- Drug: HRS8807、SHR6390
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04993430
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT04973189
- Locations
- 🇨🇳
The second Hospital of Anhui Medical University, Hefei, Anhui, China
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT04928625
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: SHR-1905/placebo
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT04905602
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04877717
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China